Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 3.57
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of ALT is 17 and suggests 377% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
